title: Genomancy: predicting tumour response to cancer therapy based on the oracle of genetics.
abstract: Cells are complex systems that regulate a multitude of biologic pathways involving a diverse array of molecules. Cancer can develop when these pathways become deregulated as a result of mutations in the genes coding for these proteins or of epigenetic changes that affect gene expression, or both1,2. The diversity and interconnectedness of these pathways and their molecular components implies that a variety of mutations may lead to tumorigenic cellular deregulation3-6. This variety, combined with the requirement to overcome multiple anticancer defence mechanisms7, contributes to the heterogeneous nature of cancer. Consequently, tumours with similar histology may vary in their underlying molecular circuitry8-10, with resultant differences in biologic behaviour, manifested in proliferation rate, invasiveness, metastatic potential, and unfortunately, response to cytotoxic therapy. Thus, cancer can be thought of as a family of related tumour subtypes, highlighting the need for individualized prediction both of disease progression and of treatment response, based on the molecular characteristics of the tumour.
authors.affiliation: Department of Public Health Sciences, Paul Mellon Urologic Cancer Institute, University of Virginia, Charlottesville, VA, U.S.A.
authors.forename: P D
authors.initials: PD
authors.lastname: Williams
authors.forename: J K
authors.initials: JK
authors.lastname: Lee
authors.forename: D
authors.initials: D
authors.lastname: Theodorescu